Skip to main content

Vir surges 50% after COVID-19 antibody drug shown to reduce risk of death

Shares of Vir Biotechnology surged 35% in premarket trading on Thursday, after the company said its experimental COVID-19 treatment, being developed with GlaxoSmithKline, significantly reduced hospitalization and death in high-risk adults.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.